NTRK fusion in CRC is rare (~0.1-0.3%) but enriched in MSI-H / Lynch syndrome CRC (~5-10%...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NTRK-FUSION-CRC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Actionability Facts
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variant | NTRK1/3 fusion (rare ~0.1-0.3%, enriched in MSI-H / dMMR CRC) |
| Disease | DIS-CRC |
| ESCAT tier | IA |
| Recommended combinations | larotrectinib monotherapy, entrectinib monotherapy |
| Evidence summary | NTRK fusion in CRC is rare (~0.1-0.3%) but enriched in MSI-H / Lynch syndrome CRC (~5-10% of MSI-H). Larotrectinib and entrectinib are FDA tumor-agnostic; CRC subset of pooled trials shows durable responses. Practical detection challenge: pan-TRK IHC has high false-positive rate in MSI-H CRC — confirm with RNA-NGS. |
Notes
ESCAT IA (tumor-agnostic actionability) — CRC has standard 1L options (chemo + EGFR/VEGF mAb) so NTRK-fusion testing is typically reserved for post-progression / panel testing. OncoKB Level 1.
Used By
No reverse references found in the YAML corpus.